Oricell
oricell.com
Actively hiring
Oncology Therapeutics
Cell & Gene Therapy
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$110M
1 round on record
Latest round
$110M
Venture round · Apr 2026 · 5 mo ago
Backers
1
Qiming Venture Partners
The money's age
Fresh money
5 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 10
Raised a round Venture round $110M · MedCity News
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2026 | $110M | — | MedCity News |
Backed byfrom the funds' portfolios and accelerator catalogs
Qiming Venture Partners Similar startupsby what they do, their industry and backers
学习平台 钉钉版 企业微信版 飞书版 北森学习云 AI 做课助手 AI 学习助手 AI 陪练 AI 领导力教练 AI 考试助手 业培一体 课程商城 解决方案 物业行业解决方案 金融保险解决方案 生产制造业解决方案 餐饮行业解决方案 零售行业解决方案 客户案例 资源中心 视频中心…
关于我们_剂泰科技（北京）股份有限公司 首页 关于我们 技术与研发 在研管线 全球合作 新闻中心 投资者关系 信息披露 招股文件 公告与通函 公司治理 业绩报告 投资者日历 投资者联系 人才与招聘 联系我们 关于剂泰科技…
首页 走进博流 产品中心 解决方案 联系我们 EN 关于博流 全无线智能AloT&边缘计算核心芯片供应商 关于博流 投资者咨询 博流动态 加入博流 博流公告 致力于 全无线智能AloT&边缘计算核心芯片供应商…
网站首页 关于我们 走进纬德 组织架构 发展历程 合作伙伴 荣誉资质 产品中心 安全加密 系统平台 安全审计 解决方案 智慧新能源解决方案 安全加密解决方案 系统平台解决方案 安全审计解决方案 新闻动态 公司动态 行业新闻 联系我们 联系方式 人才招聘 投资者关系 新闻 动态…
关于我们 康诺思腾（Cornerstone Robotics）是一家创立于香港的创新型手术机器人公司，怀着"引领医疗创新，心系天下健康"的愿景，致力于打造安全高效的手术机器人平台，提升全球范围优质医疗资源的可及性，让更多患者受益于高端医疗科技带来的高品质医疗服务。公司已在全球设立…
Lift to Zenith with Novel Myeloid Engager Therapeutics. To maximize the drugability potential, we target approaches to improve clinical…
Overview
首页 关于我们 技术平台 产品管线 临床试验 投资者关系和媒体 新闻资讯 投资者关系 职业生涯 人才培养 院士(专家)/博士后工作站 人才招聘 联系我们 EN — CN 联系我们 CN — EN 关于我们 技术平台 产品管线 临床试验 投资者关系和媒体 新闻资讯 投资者关系 职业生涯 人才培养 院士(专家)/博士后工作站 人才招聘 我感觉到我的身体在好转，不只是精神方面，我甚至可以像 从前一样从事家务琐事。事实上每一次随访也都在用数据证 明我的身体在积极恢复。作为一名晚期肝癌患者，从未敢想 象CAR-T能为我带来如此好的疗效，我现在很享受和家人一 起生活每一天！ " 胡先生 肝细胞癌…
News
Oricell Therapeutics: $110 Million Pre-IPO Financing To Advance Solid Tumor CAR-T Pipeline
Oricell Therapeutics Holdings Limited, a clinical-stage biotechnology company focused on cancer immunotherapies, announced the closing of a pre-IPO financing round exceeding $110 million to support global expansion and accelerate development of its CAR-T
Read more
Report
Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer
There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics.
Read more
Report
Oricell closes a 'pre-IPO' megaround to aim CAR-T at solid tumors
The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer.
Read more
Report
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
/PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies,...
Read more
Report
Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
/PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the...
Read more
Report
Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the closing of a $70M Series C1 financing.
Read more
Report
Financials
Total raised
$110M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $110M | Details |